GLP-1 Medications: Balancing Weight Loss Benefits and Potential Risks

Glucagon-like peptide-1 (GLP-1) receptor agonists, commonly referred to as GLP-1 medications, are used to manage type 2 diabetes, and obesity. These drugs, which include semaglutide and tirzepatide, act on the body’s natural hormonal systems to regulate blood sugar and appetite.

GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the gut. According to reporting from BS Health on October 15, 2025, these medications are designed to stimulate this natural hormone to help regulate blood sugar after eating while also affecting digestion and appetite.

Mechanism of Action

GLP-1 receptor agonists mimic the GLP-1 hormone that is naturally released in the gastrointestinal tract in response to eating. When carbohydrates are broken down into simple sugars in the bloodstream, GLP-1 triggers the release of insulin from the pancreas.

Insulin helps move glucose out of the bloodstream and into cells for nourishment and energy. In individuals with type 2 diabetes, the body may not produce enough insulin or the cells may be resistant to its effects. As noted by Harvard Health on February 5, 2024, GLP-1 agonists stimulate the pancreas to release insulin and suppress the release of glucagon, both of which help control blood sugar levels.

Beyond blood sugar regulation, these drugs act on the brain to reduce hunger and act on the stomach to delay gastric emptying. This process ensures that individuals feel full for a longer period, which can lead to weight loss.

Medical Applications and Efficacy

GLP-1 agonists have been utilized to treat type 2 diabetes for approximately two decades. More recently, the FDA has approved several of these agonists for weight loss in people with obesity who do not have diabetes.

The long-term impact of these treatments continues to be a subject of medical review. A systematic review published in Cureus on July 19, 2025, evaluated the long-term efficacy and safety of GLP-1 receptor agonists in the management of obesity. This review synthesized data from high-quality randomized controlled trials published between 2018 and 2025.

Side Effects and Safety Considerations

While effective, GLP-1 medications are associated with various side effects. Digestive issues are commonly reported as a result of the medication’s impact on the gastrointestinal tract.

Rapid weight loss associated with these drugs can also lead to physical changes in appearance. Harvard Health reported on February 5, 2024, that some users experience Ozempic face, a term used to describe the sagging and wrinkling of facial skin that can occur following rapid weight loss.

Medical professionals emphasize the importance of discussing these options with a healthcare provider to determine if a patient is a suitable candidate for GLP-1 therapy, considering their specific health goals and medical history.